Menstrual cycle variability in midazolam pharmacokinetics

Journal of Clinical Pharmacology

Volumn 39, Issue 3, 1999, Pages 275-280

  Kharasch, Evan D ^a,b   Mautz, Douglas ^b   Senn, Tauri ^b   Lentz, Gretchen ^b   Cox, Kathy ^b  

^a Anesthesiology Service   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; CYTOCHROME P450 ISOENZYME; ESTRADIOL; MIDAZOLAM; PROGESTERONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPARTMENT MODEL; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; ENZYME ACTIVITY; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLICULAR PHASE; HORMONAL REGULATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUTEAL PHASE; MENSTRUAL CYCLE; MENSTRUATION; NORMAL HUMAN; PROGESTERONE BLOOD LEVEL; STEADY STATE;

ADOLESCENT; ADULT; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HUMANS; MENSTRUAL CYCLE; METABOLIC CLEARANCE RATE; MIDAZOLAM; MIXED FUNCTION OXYGENASES;

EID: 0033055925     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Fletcher CV, Acosta EP, Strykowski JM: Gender differences in human pharmacokinetics and pharmacodynamics. J Adolescent Health 1994;15:619-629.
2. Harris RZ, Benet LZ, Schwartz JB: Gender effects in pharmacokinetics and pharmacodynamics. Drugs 1995;50:222-239.
3. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP: Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270:414-423.
4. Wrighton SA, VandenBranden M, Ring BJ: The human drug metabolizing cytochromes P450. J Pharmacokinet Biopharm 1996;24:461-473.
5. Guengerich FP: Human cytochrome P450 enzymes. In, Ortiz de Montellano PR (ed.): Cytochrome P450: Structure, Mechanism and Biochemistry. New York: Plenum, 1995;473-535.
6. Li AP, Kaminski DL, Rasmussen A: Substrates of human hepatic cytochrome P450 3A4. Toxicology 1995;104:1-8.
7. Hunt CM, Westerkam WR, Stave GM: Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol 1992;44:275-283.
8. Schmucker DL, Woodhouse KW, Wang RK, Wynne H, James OF, McManus M, et al: Effects of age and gender on in vitro properties of human liver microsomal monooxygenases. Clin Pharmacol Ther 1990;48:365-374.
9. Lemmens HJM, Burm AGL, Hennis PJ, Gladines MPPR, Bovill JG: Influence of age on the pharmacokinetics of alfentanil: gender dependence. Clin Pharmacokinet 1990;19:416-422.
10. Rubio A, Cox C: Sex, age and alfentanil pharmacokinetics. Clin Pharmacokinet 1991;21:81-82.
11. Tateishi T, Krivoruk Y, Ueng Y-F, Wood AJJ, Guengerich FP, Wood M: Identification of human liver cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation. Anesth Analg 1996;82:167-172.
12. Iribarne C, Berthou F, Baird S, Dréano Y, Picart D, Bail JP, et al: Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol 1996;9:365-373.
13. Kashuba AD, Nafziger AN: Physiological changes during the menstrual cycle and their effects on the pharmacokinetics and pharmacodynamics of drugs. Clin Pharmacokinet 1998;34:203-218.
14. Merkatz RB, Temple R, Sobel S, Feiden K, Kessler DA: Women in clinical trials of new drugs: a change in food and drug administration policy. N Engl J Med 1993;329:292-296.
15. Schuetz JD, Kauma S, Guzelian PS: Identification of the fetal liver cytochrome CYP3A7 in human endometrium and placenta. J Clin Invest 1993;92:1018-1024.
16. Yun C-H, Wood M, Wood AJJ, Guengerich FP: Identification of the pharmacogenetic determinants of alfentanil metabolism: cytochrome P450 3A4. Anesthesiology 1992;77:467-474.
17. Labroo RB, Thummel KE, Kunze KL, Podoll T, Trager WF, Kharasch ED: Catalytic role of cytochrome P4503A4 in multiple pathways of alfentanil metabolism. Drug Metab Dispos 1995;23:490-496.
18. Kharasch ED, Russell M, Mautz D, Thummel KE, Kunze KL, Bowdle TA, et al: The role of cytochrome P450 3A4 in alfentanil clearance: implications for interindividual variability in disposition and perioperative drug interactions. Anesthesiology 1997;87:36-50.
19. Kharasch ED, Russell M, Garton K, Lentz G, Bowdle TA, Cox K: Assessment of cytochrome P450 3A4 activity during the menstrual cycle using alfentanil as a noninvasive probe. Anesthesiology 1997;87:26-35.
20. Watkins PB: Noninvasive tests of CYP3A enzymes. Pharmacogenetics 1994;4:366-368.
21. Stein CM, Kinirons MT, Pincus T, Wilkinson GR, Wood AJJ: Comparison of the dapsone recovery ratio and the erythromycin breath test as in vivo probes of CYP3A activity in patients with rheumatoid arthritis receiving cyclosporine. Clin Pharmacol Ther 1996;59:47-51.
22. Thummel KE, Shen DD, Podoll T, Kunze KL, Trager WF, Hartwell P, et al: Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. J Pharmacol Exp Ther 1994;271:549-556.
23. Thummel KE, Shen DD, Podoll T, Kunze KL, Trager WF, Bacchi CE, et al: Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intra-individual hepatic CYP3A variability following liver transplantation. J Pharmacol Exp Ther 1994;271:557-566.
24. Meuldermans W, Van Peer A, Hendrickx J, Woestenborghs R, Lauwers W, Heykants J, et al: Alfentanil pharmacokinetics and metabolism in humans. Anesthesiology 1988;69:527-534.
25. Chauvin M, Bonnet F, Montembault C, Levron JC, Viars P: The influence of hepatic plasma flow on alfentanil plasma concentration plateaus achieved with an infusion model in humans: measurement of alfentanil hepatic extraction coefficient. Anesth Analg 1986;65:999-1003.
26. Yasui N, Otani K, Kaneko S, Ohkubo T, Osanai T, Sugawara K, et al: A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in alprazolam metabolism. Clin Pharmacol Ther 1996;59:514-519.
27. Kirkwood C, Moore A, Hayes P, DeVane CL, Pelonero A: Influence of menstrual cycle and gender on alprazolam pharmacokinetics. Clin Pharmacol Ther 1991;50:404-409.
28. Bäckström T, Jorpes P: Serum phenytoin, phenobarbital, carbamazepine, albumin, and plasma estradiol, progesterone concentrations during the menstrual cycle in women with epilepsy. Acta Neurol Scand 1979;59:63-71.
29. Shavit G, Lerman P, Korczyn AD, Kivity S, Bechar M, Gitter S: Phenytoin pharmacokinetics in catamenial epilepsy. Neurology 1984;34:959-961.
30. Lew KH, Ludwig EA, Milad MA, Donovan K, Middleton E, Ferry JJ, et al: Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 1993;54:402-414.
31. Engel G, Hofmann U, Heidemann H, Cosme J, Eichelbaum M: Antipyrine as a probe for human oxidative drug metabolism: identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation. Clin Pharmacol Ther 1996;59:613-623.
32. Nayak VK, Kshirsagan NA, Desai NK, Satoskar RS: Influence of menstrual cycle on antipyrine pharmacokinetics in healthy Indian female volunteers. Br J Clin Pharmac 1988;26:604-606.
33. Riester EF, Pantuck EJ, Pantuck CB, Passananti GT, Vesell ES, Conney AH: Antipyrine metabolism during the menstrual cycle. Clin Pharmacol Ther 1980;28:384-391.
34. Krivoruk Y, Kinirons MT, Wood AJ, Wood M: Metabolism of cytochrome P4503A substrates in vivo administered by the same route: lack of correlation between alfentanil clearance and erythromycin breath test. Clin Pharmacol Ther 1994;56:608-614.
35. Watkins PB, Turgeon DK, Saenger P, Lown KS, Kolars JC, Hamilton T, et al: Comparison of urinary 6-β-cortisol and the erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity. Clin Pharmacol Ther 1992;52:265-273.
36. Kinirons MT, Oshea D, Downing TE, Fitzwilliam AT, Joellenbeck L, Groopman JD, et al: Absence of correlations among 3 putative invivo probes of human cytochrome P4503A activity in young healthy men. Clin Pharmacol Ther 1993;54:621-629.
37. Lown KS, Thummel KE, Benedict PE, Shen DD, Turgeon DK, Berent S, et al: The erythromycin breath test predicts the clearance of midazolam. Clin Pharmacol Ther 1995;57:16-24.
38. Olkkola KT, Backman JT, Neuvonen PJ: Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994;55:481-485.